Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Терапевтический архив - 93(2021), 11, Seite 1306-1315 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Natalia Yu. Pshenichnaya [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral therapy |
|---|
| doi: |
10.26442/00403660.2021.11.201206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ013655124 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ013655124 | ||
| 003 | DE-627 | ||
| 005 | 20230310055943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2021.11.201206 |2 doi | |
| 035 | |a (DE-627)DOAJ013655124 | ||
| 035 | |a (DE-599)DOAJ880fd58841c14cb7b184ec79dd03505b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a Natalia Yu. Pshenichnaya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients. | ||
| 650 | 4 | |a coronaviruses | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a antiviral therapy | |
| 650 | 4 | |a umifenovir | |
| 650 | 4 | |a lopinavir | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a interferon | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Elena N. Kareva |e verfasserin |4 aut | |
| 700 | 0 | |a Irina A. Leneva |e verfasserin |4 aut | |
| 700 | 0 | |a Vilya A. Bulgakova |e verfasserin |4 aut | |
| 700 | 0 | |a Irina E. Kravchenko |e verfasserin |4 aut | |
| 700 | 0 | |a Irina V. Nikolaeva |e verfasserin |4 aut | |
| 700 | 0 | |a Antonina I. Grekova |e verfasserin |4 aut | |
| 700 | 0 | |a Antonina P. Ivanova |e verfasserin |4 aut | |
| 700 | 0 | |a Larisa V. Puzyreva |e verfasserin |4 aut | |
| 700 | 0 | |a Guzel M. Khasanova |e verfasserin |4 aut | |
| 700 | 0 | |a Svetlana N. Orlova |e verfasserin |4 aut | |
| 700 | 0 | |a Elena P. Tikhonova |e verfasserin |4 aut | |
| 700 | 0 | |a Vladimir A. Petrov |e verfasserin |4 aut | |
| 700 | 0 | |a Oleg V. Malinin |e verfasserin |4 aut | |
| 700 | 0 | |a Natalia V. Kolaeva |e verfasserin |4 aut | |
| 700 | 0 | |a Elena V. Volchkova |e verfasserin |4 aut | |
| 700 | 0 | |a Nina N. Kanshina |e verfasserin |4 aut | |
| 700 | 0 | |a Vladimir P. Chulanov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Терапевтический архив |d "Consilium Medicum" Publishing house, 2018 |g 93(2021), 11, Seite 1306-1315 |w (DE-627)DOAJ000102962 |x 23095342 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:11 |g pages:1306-1315 |
| 856 | 4 | 0 | |u https://doi.org/10.26442/00403660.2021.11.201206 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/880fd58841c14cb7b184ec79dd03505b |z kostenfrei |
| 856 | 4 | 0 | |u https://ter-arkhiv.ru/0040-3660/article/viewFile/99553/73016 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0040-3660 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2309-5342 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 11 |h 1306-1315 | ||